1037The risk factors for resistant Esherichia coli infections after prostate biopsy under fluoroquinolone prophylaxis

Background. To evaluate the risk factors of fluoroquinolone resistant or ESBL-producing E coli infections after prostate biopsy under flouroquinolone prophylaxis Methods. From January 2003 to December 2012, we evaluated the records of 2215 patients who underwent TRUS guided 12-core prostate biopsy under flouroquinolone prophylaxis. The risk factors including age, diabetes mellitus, hypertension, history of hospital admission within 30 days, prior use of quinolons within 6 months of the biopsy, first or repeat biopsy were evaluated for the development of flouroquinolon resistance and ESBL producing E coli Results. Of the 2215 patients, 153 had positive urine cultures such as 129 (84.3%) E coli, 8 (5.2%) Enterococcus spp, 6 (3.9%) Enterobacter spp, 5 (3.2%) Pseudomonas spp, 3 (1.9%) MRCNS, 2 (1.3%) Klebsiella spp. Of the positive urine cultures yielded E coli, 99 (76.7%) were evaluated for fluoroquinolone (ciprofloxacin) resistance. In these group 83 (83.8%) were fluoroquinolone resistant. In addition to 129 E coli strains were examined for ESBL producing and ESBL positivity was found in 67 (51,9%) of these strains. When the risk factors regarding the infection caused by ESBL producing or quinolon resistant E coli strains were examined, the use of quinolones in the last 6 months and a history of hospitalization in the last 30 days were found to be significant (p = 0,00, p = 0,021 and p = 0,034, p = 0,041 respectively) Conclusion. We found that while fluoroquinolone prophylaxis started before TRUS-guided prostate biopsy is still effective in preventing infectious complications that might develop after biopsy, fluoroquinolone-resistant or ESBLproducing E coli strains might be a common microorganism in patients with this kind of complication. This study examined various risk factors for the development of infection in both ESBL-producing strains and strains that developed resistance to fluoroquinolones. Among these factors, a history of the use of fluoroquinolones in the last 6 months and hospitalization in the last one month were found to be significant. Disclosures. All authors: No reported disclosures.